(Lecture, May. 21) Notice on the academic presentation of Dr. Zhang Yingjun of Guangdong Dongsunshine Pharmaceutical Co., LTD

Title：Innovative drug development and industrialization - a brief analysis of the biomedical industry and an overview of the experience of new drug development in enterprises

Time: Tuesday, May 21, 2024 2:30-4:00 p.m

Venue: Conference room 4th floor, Shaw Engineering Building

[Biography]

Zhang Yingjun, Chairman of Guangdong Dongsunshine Pharmaceutical Co., LTD., President of Pharmaceutical Research Institute. National young and middle-aged scientific and technological innovation leading talents, executive Deputy director of the National Key Laboratory for the Research and Development of Anti-Infective New drugs and member of the academic Committee, member of the Pharmaceutical Chemistry Committee of the National Pharmaceutical Society, China Patent examination technical expert of the State Intellectual Property Office, Chairman of the Pharmaceutical Chemistry Committee of Guangdong Province. In recent years, he has presided over more than 50 category 1 innovative drug research, with more than 16 years of drug development and management experience, and has deep attainments in the fields of infection, tumor and chronic disease. So far, he has published more than 40 papers in important academic journals at home and abroad, and served as the editorial board of several well-known domestic journals. In the field of new molecular innovative drug therapy, it has applied for more than 1,200 invention patents, of which 136 PCT patents, more than 700 have been authorized, of which more than 230 invention patents have been obtained as the first inventor.

[Abstract]

Based on the current status of the global biopharmaceutical industry, the report focuses on the development of China's biopharmaceutical industry, and briefly Outlines the latest and hottest biopharmaceutical technologies in the world. This paper introduces the research and development process of innovative drugs, including how to establish projects, compound screening methods, main contents of pre-clinical and clinical studies, and the final listing and commercialization of innovative drugs, and provides some new insights into the research and development of innovative drugs in combination with the research and development experience of many innovative drugs listed or about to be listed in Dongsunshine Pharmaceutical.

Announced by School of Chemistry and Chemical Engineering